Jun-Ichi Mimaya
Overview
Explore the profile of Jun-Ichi Mimaya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
127
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koga Y, Kumagai M, Takimoto T, Mimaya J, Nakazawa A, Horibe K, et al.
Rinsho Ketsueki
. 2012 Jun;
53(4):443-9.
PMID: 22687978
Hodgkin lymphoma is an easily curable malignancy in the pediatric age group and is less frequently observed in Japan. No study with a large sample size of Japanese patients has...
2.
Shirahata A, Fujisawa K, Ishii E, Ohta S, Sako M, Takahashi Y, et al.
J Pediatr Hematol Oncol
. 2009 Jan;
31(1):27-32.
PMID: 19125083
Background: We evaluated the clinical pictures, outcome for childhood idiopathic thrombocytopenic purpura (ITP) and the trends of the choice of management for childhood ITP in Japan. Method: Every year, questionnaires...
3.
Ryo A, Tsurutani N, Ohba K, Kimura R, Komano J, Nishi M, et al.
Proc Natl Acad Sci U S A
. 2008 Jan;
105(1):294-9.
PMID: 18172216
Human immunodeficiency virus type 1 (HIV-1) utilizes the macromolecular machinery of the infected host cell to produce progeny virus. The discovery of cellular factors that participate in HIV-1 replication pathways...
4.
Hoshino S, Sun B, Konishi M, Shimura M, Segawa T, Hagiwara Y, et al.
AIDS Res Hum Retroviruses
. 2007 Apr;
23(3):391-7.
PMID: 17411372
Vpr, an accessory gene product of HIV-1, has been reported in the plasma of HIV-1-positive patients, and exogenous Vpr induces the reactivation of viral production from latently infected cells and...
5.
Nishio N, Mimaya J, Nara T, Takashima Y, Horikoshi Y, Urushihara N, et al.
Pediatr Int
. 2006 Dec;
48(6):531-5.
PMID: 17168969
Background: In Japan, mass screening for neuroblastoma has been performed at 6 months of age to improve the prognosis of this condition for more than 20 years. In recent years,...
6.
Nishio N, Mimaya J, Horikoshi Y, Okada N, Nara T, Takashima Y, et al.
J Pediatr Hematol Oncol
. 2006 Aug;
28(8):537-9.
PMID: 16912596
Neuroblastoma is the most common extracranial solid tumor in childhood. Spontaneous regression has been well described in infants, especially in those with stage 4S and those with low-stage neuroblastoma detected...
7.
Shitara T, Shimada A, Hanada R, Matsunaga T, Kawa K, Mugishima H, et al.
Pediatr Hematol Oncol
. 2006 May;
23(2):103-10.
PMID: 16651238
Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m2/day for 3 consecutive days, repeated once after 25...
8.
Munkanta M, Terunuma H, Takahashi M, Hanabusa H, Miura T, Ikeda S, et al.
Viral Immunol
. 2005 Oct;
18(3):500-5.
PMID: 16212528
Approximately 30% of patients with hemophilia in Japan were infected with human immunodeficiency virus (HIV) in early 1980s through contaminated blood products. In 1995, a cohort of HIV-infected, asymptomatic patients...
9.
Okazaki T, Kohno S, Mimaya J, Hasegawa S, Urushihara N, Yoshida A, et al.
Pediatr Surg Int
. 2003 Dec;
20(1):27-32.
PMID: 14689211
Japan has a nationwide mass-screening program for neuroblastoma in 6-month-old infants. Neuroblastoma can regress spontaneously, and some institutions observe selected cases. We evaluated the management of screened neuroblastoma at our...
10.
Mugishima H, Matsunaga T, Yagi K, Asami K, Mimaya J, Suita S, et al.
J Pediatr Hematol Oncol
. 2002 May;
24(2):94-100.
PMID: 11990713
Purpose: To determine the dose-limiting toxicity, maximum tolerated dose, and potential efficacy of irinotecan in children with refractory malignant solid tumors. Patients And Methods: In the present phase I clinical...